Here's how ASX 200 healthcare shares performed in June

Healthcare shares were a tad ill in June.

| More on:
Two researchers discussing results of a study with each other.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • ASX healthcare shares struggled last month 
  • As a basket, the group finished down, and there wasn't much joy to talk about 
  • These three shares were star performers last year but have reversed course in 2022 

ASX 200 healthcare shares were defensive in June but finished the month down overall.

The benchmark S&P/ASX 200 Health Care Index (ASX: XHJ) was volatile, slipping 3% in June. Nevertheless, there were some names worth mentioning. Let's take a look.

CSL Limited (ASX: CSL)

Shares in biotech giant CSL finished June down but managed to bounce from a low of $255 on 17 June to finish at $269 apiece.

It was a quiet month for CSL, however, the company's large market cap and defensible industry arguably helped it through the month relatively unscathed.

The $129 billion company by market cap is also tipped to soar past $300 per share by those at Cameron Harrison.

Analysts at the firm note that CSL is positioned to benefit from tailwinds in its plasma collection and influenza vaccine businesses.

CSL shares are down 4.5% over the last 12 months.

Immutep Ltd (ASX: IMM)

Another ASX 200 share to mention is Immutep. Its shares were extremely volatile last month, trading as low as 14 cents and as high as 24 cents.

Despite continued updates regarding its lead drug candidate, etfi, investors appear to have overlooked the share in favour of more systematic risks plaguing the markets.

Immutep has several trials that are investigating etfi's efficacy in a number of applications. Etfi has been recognised at the recent American Society of Clinical Oncology (ASCO) 2022 Special Edition.

Immutep shares are down 51% into this year to date.

Incannex Healthcare Ltd (ASX: IHL)

Another share that struggled last month was Incannex Healthcare. Again investors were mute to updates on the company's drug studies in June.

For instance, on 2 June, it announced positive results from a phase 2 clinical trial investigating the effect of one of its drug candidates, IHL-42X.

It was being tested for treatment of obstructive sleep apnoea.

After a minor jump, the Incannex share price cratered in the days afterwards. It hasn't stopped trading down and investors are unloading their positions at pace.

Incannex now trades 65% down this year to date and 16% in the past 12 months.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 ASX 200 healthcare stocks that could deliver big returns for investors

Analysts see a lot of value in these stocks at current levels.

Read more »

A team of people giving the thumbs up sign representing APA and Wesfarmers doing a deal to study green hydrogen transport using an APA gas pipeline
Healthcare Shares

Why are so many top fundies overweight on CSL shares?

This is a healthy opportunity, according to a number of fund managers.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Share Fallers

Why did this ASX All Ords stock just crash 16%?

Investors are punishing this ASX All Ords stock on Thursday. But why?

Read more »

woman in lab coat conducting testing representing biotech
Healthcare Shares

Can the CSL share price really reach $500 in just 3 years?

Leading analysts are expecting big returns from CSL shares in the months ahead.

Read more »

Two businesspeople walk together in an office, smiling as they enjoy a good business relationship.
Healthcare Shares

Why two brokers have named this ASX 200 stock as a best buy

Investors may want to pounce on this high-quality stock before it's too late.

Read more »

A young man goes over his finances and investment portfolio at home.
Healthcare Shares

What could $5,000 invested in CSL shares become in 1 year?

Let's see what sort of returns analysts are tipping for this ASX giant.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Why is everyone talking about Mesoblast shares?

ASX biotech share Mesoblast has been grabbing plenty of investor attention recently.

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Why the Mesoblast share price can rise another 60%

The big gains may not be over according to Bell Potter.

Read more »